Thermo Scientific nProber IV Delivers Faster, Easier Failure Analysis Process for Semiconductor Labs

Thermo Scientific nProber IV Delivers Faster, Easier Failure Analysis Process for Semiconductor Labs New platform provides faster identification of defects that impact device performance HILLSBORO, Ore., July 30, 2020 /PRNewswire/ — Thermo Fisher Scientific today released the Thermo Scientific nProber IV nanoprober platform, a fault isolation system used by semiconductor fabs to precisely locate and... Read more

Bruker Launches Revolutionary High-Speed AFM System for Single-Molecule Applications

JPK NanoRacer® Follows Molecular Dynamics in Real Time at 50 Frames per Second BERLIN–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today announced the release of the NanoRacerhigh-speed AFM system. With an unprecedented imaging speed of 50 frames per second, this sets a new milestone in high-speed scanning capabilities to enable true real-time visualization of dynamic biological... Read more

Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia

COVACTA trial did not meet its primary endpoint of improved clinical status in patients with COVID-19 associated pneumonia, or the key secondary endpoint of reduced patient mortality The study is the first global, randomised, double-blind, placebo-controlled phase III trial investigating Actemra/RoActemra in this setting Roche remains committed to continuing the Actemra/RoActemra clinical trial programme in... Read more

Phase III data show Roche’s Port Delivery System with ranibizumab enabled over 98% of patients to go six months between treatments for neovascular age-related macular degeneration

In the Archway study, Port Delivery System with ranibizumab (PDS) demonstrated non-inferior and equivalent visual acuity outcomes compared with monthly ranibizumab eye injections, and a favourable benefit-risk profile PDS is a permanent refillable eye implant that continuously delivers a customised formulation of ranibizumab over a period of months, potentially reducing the treatment burden associated with... Read more

Successful Installation of ETH 1.2 GHz NMR System Enables Novel Research Capabilities in Solid-State NMR

ETH Zürich Accepts Bruker 1.2 GHz NMR Spectrometer BILLERICA, Mass.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today announced the successful installation and customer acceptance of the Avance™ NEO 1.2 GHz NMR system at the Department of Chemistry and Applied Biosciences of the Eidgenössische Technische Hochschule (ETH) Zürich (www.ethz.ch) in Switzerland. Following the acceptance of the world’s... Read more

QIAGEN announces publication of Supplemental Reasoned Position Statement for proposed acquisition by Thermo Fisher

Venlo, the Netherlands, July 22, 2020 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the publication of its Supplemental Reasoned Position Statement in response to the amended Offer Document published by Thermo Fisher Scientific Inc (NYSE: TMO) on July 17, 2020. The Offer Document relates to the recommended offer by Thermo Fisher... Read more

JEOL Begins Remote Demonstrations of New Ultrahigh Resolution Field Emission SEM in July

July 1, 2020 Peabody, Mass. – The launch of a new JEOL Field Emission Scanning Electron Microscope during the summer of 2020 includes virtual demonstrations of its powerful performance directly to those in the market for an analytical ultrahigh resolution SEM. JEOL’s new JSM-IT800 is the company’s top-of-the-line microscope with ultrahigh spatial resolution imaging and... Read more

Luminex Delivers xMAP® INTELLIFLEX Systems to Life Science Research Partners

AUSTIN, Texas, July 1, 2020 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that the company has delivered the first of its new xMAP® INTELLIFLEX Systems to several of its Life Science Research Partners, achieving a major milestone in the company’s strategy to extend its xMAP Technology with new functionality to facilitate new applications. Initially intended... Read more

QIAGEN shareholders approve all agenda items related to acquisition by Thermo Fisher Scientific at Annual General Meeting

Venlo, the Netherlands, June 30, 2020 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced that its shareholders today approved all agenda items at the Company’s Annual General Meeting related to the proposed voluntary public takeover offer for the acquisition of all ordinary shares in QIAGEN by Quebec B.V., a wholly-owned subsidiary of Thermo... Read more